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Introduction: Comorbidity may be an important prognostic factor
in the treatment of small cell lung carcinoma (SCLC). This study
aimed to investigate the prognostic values of simplified comorbidity
score (SCS) in the treatment of patients with SCLC.
Methods: The patients with SCLC admitted to the National Taiwan
University Hospital during the period from January 2000 to Decem-
ber 2006 were included. The medical records were reviewed and
analyzed. The SCS was used to evaluate comorbidities of the
patients. A Cox proportional hazard model was used to calculate the
hazard ratio (HR) and 95% confidence intervals (CIs) for age,
gender, and factors significantly associated with survival identified
in univariate analyses.
Results: A total of 172 patients were included; 56 patients had
limited-stage disease and 116 had extensive-stage disease. Patients
with an SCS more than 9 had shorter overall survival than those with
SCS 9 both in limited-stage (372 days versus 581 days, p  0.01)
and extensive-stage disease (215 days versus 324 days, p  0.001).
Multivariate analysis indicated that SCS more than 9 was associated
with a worse prognosis in patients with limited-stage disease (HR:
2.17, 95% CI: 1.12–4.21) and extensive-stage disease (HR: 1.74,
95% CI: 1.12–2.72), respectively. For patients with extensive-stage
disease, SCS more than 9 was associated with poor treatment
response (9 versus 9, disease response rate: 60.0% versus
82.4%, p  0.02).
Conclusions: The SCS may be an independent prognostic factor for
patients with SCLC. Large-scale prospective studies may be re-
quired to validate the prognostic value of the SCS for SCLC.
Key Words: Small cell lung carcinoma, Comorbidity, Prognostic
factor.
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Small cell lung carcinoma (SCLC) is characterized by earlydissemination, good initial treatment response, early re-
lapse, and a more aggressive nature than non-small cell lung
carcinoma (NSCLC).1 SCLC accounts for approximately
13% and 8.1% of all lung cancer subtypes in the United
States and Taiwan, respectively.2,3 The median survival time
for limited-stage SCLC is 12 to 17 months and that for
extensive-stage SCLC is 7 to 9 months.4,5 The incidence of
SCLC has decreased and a modest improvement in survival
has been observed between 1973 and 20022; however, the
long-term outlook remains poor.
For patients with SCLC, good performance status,
limited-stage disease, and female gender are associated with
a better prognosis than the converse. Elevated lactate dehy-
drogenase (LDH) levels also carry an unfavorable out-
come.6–12 Patients with old age, low serum sodium levels, or
reduced hemoglobin levels were also reported to have a
worse prognosis.6,7,12,13 The factors associated with treatment
response in SCLC include disease extent, performance status,
gender, blood leukocyte count, and hemoglobin level.11,14
The impact of comorbidity has been emphasized in
the treatment of patients with NSCLC. Scoring systems
using weighted items to quantify patients’ comorbidity
burden have been used to predict treatment outcomes.15–18
The Charlson comorbidity index score (CCIS) predicts
surgical risk in patients operated on for NSCLC.18 The
presence of comorbidity (CCIS 1) is also related to a poor
survival in patients with NSCLC receiving systemic chemo-
therapy.15 Multivariate analysis performed in a previous
study did not show prognostic value of the CCIS for patients
with limited-stage SCLC.19
Recent studies have validated simplified comorbidity
score (SCS) as an independent prognostic factor in the treat-
ment of NSCLC.16,17 Nevertheless, the prognostic value of
SCS has not been investigated in SCLC. Therefore, we
investigated the prognostic value of comorbidity determined
using the SCS in the treatment of patients with SCLC.
PATIENTS AND METHODS
Patients
We included patients who were newly diagnosed with
SCLC and received platinum-based chemotherapy between
January 2000 and December 2006 at the National Taiwan
University Hospital, a 2150-bed tertiary teaching hospital in
northern Taiwan. The patients were identified using a com-
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puter registration database by using the International Classi-
fication of Diseases, Ninth Revision, coding system. SCLC
was diagnosed on the basis of histologic examination of
biopsy specimens or by fine-needle aspiration cytology ex-
amination. Exclusion criteria included patients receiving pal-
liative care and patients with a histologic type that indicated
combined SCLC and NSCLC. The hospital’s Institutional
Review Board approved the study protocol and waived the
need to obtain informed consent because of the retrospective
design of the study.
Data Collection
The medical records of the patients were reviewed and
analyzed for clinical characteristics, including age, gender,
tobacco consumption, disease stage, Eastern Cooperative On-
cology Group (ECOG) performance status, comorbid condi-
tions, laboratory data, treatment modalities and response, and
dates of death or last visit.
Disease staging was performed using the Veterans
Administration Lung Study Group system,20 and the stage
was determined by examining the computed tomography scan
of the thorax and upper part of the abdomen, brain computed
tomography scan, and radionuclide scan of the bone system.
Comorbid conditions before chemotherapy were as-
sessed by using the SCS.16 Briefly, seven comorbid condi-
tions were included in the SCS: tobacco consumption
(weighting 7; total lifelong consumption of at least 100
cigarettes); diabetes mellitus (weighting 5; under medication
control), renal insufficiency (weighting 4; creatinine clear-
ance 60 ml/min by the Cockroft formula), respiratory
conditions (weighting 1; history of tuberculosis, pleural ef-
fusion, pneumonia, asthma, pulmonary embolism, chronic
hypoxemia 60 mm Hg, and chronic obstructive pulmonary
disease with a forced expiratory volume in 1 second (FEV1)
1.5 liter), cardiovascular conditions (weighting 1; conges-
tive heart failure, ischemic cardiopathy, severe valvular car-
diopathy, arrhythmia under chronic treatment, history of
cardiovascular disease, and peripheral vascular disease), neo-
plastic conditions (weighting 1; previous cancer history), and
alcoholism (weighting 1; daily consumption of 80 g of
alcohol in men and40 g in women). Patients’ comorbidities
were also assessed by using CCIS for comparison.21 The
cutoff point at which the patient is considered to have a high
comorbidity score was set at 9 for the SCS and at 2 for the
CCIS.15–17
The patients were divided into two groups: 70
years and less than 70 years according to previous elderly
specific analyses for oncology patients.16,22–25 Anemia was
defined as hemoglobin level less than 12.11 In the study
hospital, the lower normal limit of serum sodium level was
135 mmol/liter. Low sodium level was defined as below
135 mmol/liter. The following laboratory parameters were
divided into high and normal groups by using the upper
normal limits as the cutoff point: serum LDH level, 460
U/liter; serum carcinoembryonic antigen, 5.0 ng/ml; and
platelet count, 320  103/l.
Treatment response was assessed by the Response
Evaluation Criteria in Solid Tumors (RECIST) criteria26 for
patients who received at least two cycles of platinum-based
chemotherapy. Disease response rate was defined as the
percentage of patients who achieved complete remission or
partial response.
Overall survival was defined as the period from the date
of diagnosis to the date of all-cause death. The patients were
followed up until December 31, 2008, or until the date of
their death.
Statistics
Exploratory analyses were performed, and the results
were expressed as mean, standard deviation, or percentage.
The 2 test or Fisher’s exact test were used to compare
categorical data between two patient groups. The indepen-
dent-samples t test was used to compare continuous variables.
The concordance of the two comorbidity scores was tested by
using  coefficient of reliability and McNemar test of sym-
metry. The correlation of the two comorbidity scores was also
tested by correlations of Spearman (Rho). A p value 0.05
was considered to be significant. Survival functions were
analyzed by the Kaplan-Meier method. Log-rank tests were
performed to compare the difference in survival between
patients groups in terms of different variables.
Cox proportional hazard models were used to calculate
hazard ratios (HRs) and 95% confidence intervals (CIs).
Univariate analyses were conducted to examine unadjusted
associations between patient groups with each individual
independent variable. Factors significantly associated with
survival in univariate analyses (p  0.05), plus age and
gender, were included in the multivariate analysis.
RESULTS
Clinical Characteristics
Between January 2000 and December 2006, 229 pa-
tients were diagnosed with SCLC at National Taiwan Uni-
versity Hospital. A total of 172 patients were included.
Among the 57 patients excluded, 47 patients received pallia-
tive care, seven had a histologic diagnosis of combined SCLC
and NSCLC, and three received chemotherapy consisting of
a nonplatinum-based regimen (cyclophosphamide, adriamy-
cin, and vincristine). The clinical characteristics of patients
included in the study are presented in Table 1. The median
age was 68 years (range: 40–92 years). Most were current
smokers or exsmokers (94.8%), men (89.5%), had an ECOG
performance status of 0 to 1 (71.5%), and had extensive-stage
disease (67.4%) at diagnosis. The median value of the SCS
was 8 (range: 0–17). The median value of the CCIS was 1
(range: 0–5). The most common comorbidity was cardiovas-
cular disease (42.4%). Mean value of hemoglobin levels was
12.6 1.8 g/dl; platelet count, 266.8 96.1 103/l; serum
sodium level, 135.6  6.7 mmol/liter; and serum LDH level,
866.0  1051.0 U/liter. Body weight measurements were
missing from the available medical records in seven patients,
and creatinine clearance could not be calculated. CCIS was
calculated for 172 patients, whereas SCS was calculated for
165 patients. A statistical concordance and a statistically
significant asymmetry were shown on Table 2 ( coefficient
of reliability  0.378; p  0.0001; McNemar test of sym-
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metry; p  0.0002). The correlation between the two scores
was positive and significant (Rho  0.55; p  0.0001).
Treatment Distribution and Response
A total of 147 patients (85.5%) received at least two
cycles of platinum-based chemotherapy. Among the 25 pa-
tients receiving less than two cycles of chemotherapy, 22 had
extensive-stage disease, 17 were aged 70 years or older, and
17 had a SCS more than 9. Of the 56 patients with limited-
stage disease, 40 patients (71.4%) received concurrent che-
moradiotherapy and 16 received only systemic chemother-
apy. Eleven patients (19.6%) received prophylactic cranial
irradiation. Of the 116 patients with extensive-stage disease,
four patients (3.4%) received prophylactic cranial irradiation.
Of the 53 evaluable patients with limited-stage disease,
the disease response rate was 86.8%. An ECOG performance
status of 2 to 4 (0–1 versus 2–4, disease response rate: 92.7%
versus 66.7%, p  0.04) and hemoglobin level less than 12
g/dl (12 versus 12, disease response rate: 64.3% versus
94.9%, p  0.01) were associated with poor treatment re-
sponse, whereas CCIS 2, SCS more than 9, age 70 years,
sodium level less than 135 mmol/liter, and LDH level more
than 460 U/liter were not.
Of the 94 evaluable patients with extensive-stage dis-
ease, the disease response rate was 73.4%. An SCS more than
9 (9 versus9, disease response rate: 60.0% versus 82.4%,
p  0.02) and an ECOG performance status of 2 to 4 (0–1
versus 2–4, disease response rate: 78.7% versus 52.6%, p 
0.02) were associated with poor treatment response, whereas
a CCIS 2, age 70 years, sodium level less than 135
mmol/liter, LDH level more than 460 U/liter, and hemoglobin
less than 12 g/dl were not.
Survival and Prognostic Factors
During the follow-up period, a total of 153 deaths
occurred (89.0%). Eleven patients were lost to follow-up, and
eight patients were still alive at the end of the follow-up
period. In limited-stage disease, overall survival was signif-
icantly longer in patients with SCS 9 than those with SCS
more than 9 (median survival: 581 days versus 372 days, p
0.01, Figure 1A). In extensive-stage disease, overall survival
was significantly longer in patients with SCS 9 than those
with SCS more than 9 (median survival: 324 days versus 215
days, p  0.001, Figure 1B).
In limited-stage disease, factors associated with poor
prognosis in univariate analyses are presented in Table 3,
including SCS more than 9 and hemoglobin level less than 12
g/dl. In multivariate analyses, SCS more than 9 (HR: 2.17,
95% CI: 1.12–4.21) and hemoglobin level less than 12 g/dl
(HR: 3.54, 95% CI: 1.56–8.03) were associated with poor
prognosis (Table 3).
TABLE 1. The Clinical Characteristics of 172 Patients with
Small Cell Lung Carcinoma
Clinical Characteristics No. (%)
Age
70 yr 99 (57.6)
70 yr 73 (42.4)
Gender
Male 154 (89.5)
Female 18 (10.5)
Stage
Limited 56 (32.6)
Extensive 116 (67.4)
ECOG performance status
0–1 123 (71.5)
2–4 49 (28.5)
CCIS
2 117 (68.0)
2 55 (32.0)
SCS (n  165)
9 84 (50.9)
9 81 (49.1)
Smoking
Current/exsmoker 163 (94.8)
Nonsmoker 9 (5.2)
Comorbidity
Diabetes mellitus 33 (19.2)
Renal insufficiency (n  165) 72 (43.6)
Cardiovascular 73 (42.4)
Respiratory 47 (27.3)
Alcoholism 11 (6.4)
Neoplastica 6 (3.5)
LDH (n  156; U/liter)
460 113 (72.4)
460 43 (27.6)
Serum sodium level (n  169; mmol/liter)
135 117 (69.2)
135 52 (30.8)
Serum CEA level (n  140; ng/ml)
5 82 (58.6)
5 58 (41.4)
Hemoglobin level (g/dl)
12 113 (65.7)
12 59 (34.3)
Platelet count (103/l)
320 129 (75.0)
320 43 (25.0)
a Two patients had prostate cancer, and the other four had nasopharyngeal cancer,
bladder cancer, laryngeal cancer, and esophageal cancer, respectively.
ECOG, Eastern Cooperative Oncology Group; CCIS, Charlson comorbidity index
score; SCS, simplified comorbidity score; LDH, lactate dehydrogenase; CEA, carcino-
embryonic antigen.
TABLE 2. The Concordance of SCS and CCIS in the 165
Patients with Small Cell Lung Carcinoma
CCIS
SCS
<9 >9 Total
2 72 39 111
2 12 42 54
Total 84 81 165
 coefficient of reliability  0.378; p  0.0001, and McNemar test of symmetry;
p  0.0002.
SCS, simplified comorbidity score; CCIS, Charlson comorbidity index score.
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In extensive-stage disease, factors associated with poor
prognosis in univariate analyses are presented in Table 4,
including age70 years, ECOG performance status of 2 to 4,
SCS more than 9, less than two cycles of chemotherapy,
sodium level less than 135 mmol/liter, and hemoglobin level
less than 12 g/dl. In multivariate analyses, SCS more than 9
was associated with poor prognosis (HR: 1.74, 95% CI:
1.12–2.72). Less than two cycles of chemotherapy (HR:
17.77, 95% CI: 7.65–41.27), sodium level less than 135
mmol/liter (HR: 2.77, 95% CI: 1.74–4.41), hemoglobin level
less than 12 g/dl (HR: 1.84, 95% CI: 1.19–2.84), and male
gender (HR: 2.28, 95% CI: 1.15–4.52) were significantly
associated with poorer outcomes (Table 4).
DISCUSSION
This study showed that a high SCS (9) was an
independent, negative prognostic factor for patients with
SCLC both in limited-stage and extensive-stage. In addition,
SCS 9 was also associated with a better treatment response
in patients with SCLC with extensive-stage disease.
The impact of comorbidity on the management of
patients with cancer can be viewed in various ways. First,
FIGURE 1. Kaplan-Meier survival curves showed that overall survival was better in patients with small cell lung carcinoma
(SCLC) with SCS 9 than those with simplified comorbidity score (SCS) 9 both in limited-stage (A, p  0.01) and extensive-
stage (B, p  0.001).
TABLE 3. Univariate and Multivariate Analyses of Factors Associated with Survival in
Patients with Limited-Stage SCLC (n  56)
Clinical Characteristics
Univariate Multivariate
HR (95% CI) p HR (95% CI) p
Age 70 yr 1.26 (0.70–2.24) 0.44 0.81 (0.40–1.64) 0.56
Male gender 0.55 (0.21–1.40) 0.21 1.51 (0.45–5.00) 0.50
ECOG performance status 2–4 0.93 (0.48–1.81) 0.84
SCS 9 2.10 (1.15–3.84) 0.02 2.17 (1.12–4.21) 0.02
CCIS 2 1.52 (0.83–2.80) 0.18
Less than two cycles of chemotherapy 0.91 (0.22–3.78) 0.90
LDH 460 U/liter 1.66 (0.87–3.17) 0.12
Sodium level 135 mmol/liter 1.11 (0.58–2.11) 0.76
Hemoglobin level 12 g/dl 2.28 (1.20–4.32) 0.01 3.54 (1.56–8.03) 0.003
CEA level 5 ng/ml 1.08 (0.54–2.17) 0.82
Platelet count 320103/l 1.53 (0.78–2.99) 0.22
HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; CCIS, Charlson comorbidity index
score; SCS, simplified comorbidity score; LDH, lactate dehydrogenase; CEA, carcinoembryonic antigen; SCLC, small cell lung
carcinoma.
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comorbidity may alter the treatment modality.27 In patients
with lung cancer, the use of cisplatin is of concern due to the
unfavorable side effects of emesis and nephrotoxicity,28 es-
pecially in patients with poor renal reserve. Second, comor-
bidity may worsen the physical condition and hinder the
treatment process.27 Similarly, in our study, patients with
SCS 9 tended to receive more than two cycles of chemo-
therapy and were associated with a better disease response
rate in patients with extensive-stage disease. The SCS may be
helpful in predicting treatment course, response, and progno-
sis for patients with SCLC.
In this study, SCS more than 9 was associated with
shorted survival time in both limited-stage and extensive-
stage, whereas CCIS 2 was not. The CCIS, first described
in 1987 in a longitudinal study, is the sum of 19 weighted
comorbidities based on the 1-year mortality rates of 559
medical patients.21 The CCIS had been used to predict sur-
vival in various cancers, including lung, head and neck,
prostate, and colon cancer.29–33 Nevertheless, the CCIS was
not originally designed for patients with cancer. The SCS,
first described in 2005, contains only seven weighted items16
and may be of great convenience in routine clinical practice.
The SCS was originally validated on the basis of heavy-
smoking patients with NSCLC, which is similar to the SCLC
patient population. Compared with the CCIS, the SCS is more
informative in the extended NSCLC validation population.17
The SCS give much weight to renal insufficiency (weighting
4), whereas the CCIS give the less weight to renal insuffi-
ciency (weighting 2). Besides, the SCS may more accurately
estimate the renal reserve in the elderly by using creatinine
clearance rather than serum creatinine used by the CCIS.
Because renal function plays an important role in the phar-
macokinetics of chemotherapy regimens, the difference of
weighting and measurements may lead to a better prognostic
value of SCS for patients with SCLC.
Advanced age remains a major concern in SCLC.34
Because of concerns about poor tolerance to chemotherapy,
attenuating the doses used in the chemotherapy regimen has
been attempted. This practice may contribute to lower toxic-
ity and to lower response rates and inferior survival.25 Pre-
vious studies have demonstrated that advanced age is asso-
ciated with a poor survival6,7,12,13; nevertheless, the impact of
comorbidity was not taken into consideration. In this study,
after adjusting for other prognostic factors, advanced age was
not associated with poor prognosis. Our findings are similar
to results reported in patients with NSCLC by Asmis et al.,15
namely, that presence of comorbid conditions, rather than old
age, correlates with poor outcomes. Because the elderly may
still retain a fair amount of functional reserve in many
organs,35 treatment modalities in the elderly should be based
on patients’ actual physical condition rather than on their
chronological age.
Our study has some limitations. First, this is a single-
unit, hospital-based study that lacked the validation of SCS in
another study population. Further multicenter study is war-
ranted to validate the use of SCS in the treatment of SCLC.
Second, the treatment response and the survival analyses
were assessed separately for limited- and extensive-stage
disease. The number of patients with limited-stage disease
was relatively small. The findings should be interpreted
carefully. Finally, the correlation of the toxicity profile with
the dosage of chemotherapy could not be recorded thoroughly
due to the retrospective nature of the study design. This study
may have been more persuasive if tolerance and quality of
life were also investigated and compared with comorbid
conditions.
In conclusion, the SCS may be an independent prog-
nostic factor for patients with SCLC both in limited-stage and
extensive-stage SCLC. Further studies are warranted to ac-
cumulate more evidence and to validate the use of the SCS in
predicting the prognosis of patients with SCLC.
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